Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to R

AIDS Clinical Trials Group Protocol 076 demonstrated that a specific zidovudine regimen reduced perinatal HIV transmission risk by approximately two-thirds. These updated recommendations from the U.S. Public Health Service Task Force detail the trial's results, discuss limitations, and provide guidance for tailoring therapy to individual patients. The document is authored by the Centers for Disease Control and Prevention.

Use Cases

• Analyzing the efficacy of a specific antenatal, intrapartum, and postnatal drug regimen based on the described clinical trial results.
• Studying the translation of clinical trial evidence into public health practice guidelines based on the recommendation structure.
• Examining considerations for patient-specific clinical decision-making in HIV care based on the discussion of tailoring therapy.

Strengths

• Based on a landmark clinical trial (ACTG 076) that reported a specific two-thirds reduction in transmission risk.
• Provides detailed recommendations for medical monitoring of pregnant women and infants receiving the therapy.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

Centers for Disease Control and Prevention (U.S.)

Collection Method

Summarizes results and recommendations from the AIDS Clinical Trials Group Protocol 076.

Geography

United States